Drugs / MMRII
last change Jul 2011 re-read 2 minutes ago

MMRII

Vaccine

Developed for
measles
Investigated by
Merck Sharp & Dohme LLC · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00000815 ? → Aug 2001 HIV infectious disease, measles National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as M-M-R-II “measles, mumps, and rubella, live attenuated (MMRII) vaccine at 12 months of age” PMID 21666159 Jul 2011
1

“Biological: M-M-R-IINCT00000815

Modality Vaccine “measles, mumps, and rubella, live attenuated (MMRII) vaccinePMID 21666159 Jul 2011
Route Subcutaneous “administered subcutaneously” NCT00000815